BioArctic AB (publ) (BIOA-B.ST)
SEK 177.2
(5.41%)
SEK 177.2
(5.41%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 139.5 Million SEK | 93.58% |
| 2022 | 72.06 Million SEK | -33.92% |
| 2021 | 109.05 Million SEK | -23.75% |
| 2020 | 143.01 Million SEK | -31.52% |
| 2019 | 208.83 Million SEK | -44.36% |
| 2018 | 375.3 Million SEK | -25.59% |
| 2017 | 504.34 Million SEK | -22.07% |
| 2016 | 647.21 Million SEK | 2735.43% |
| 2015 | 22.82 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 202.61 Million SEK | 41.09% |
| 2024 Q1 | 143.6 Million SEK | 2.94% |
| 2023 Q1 | 69.56 Million SEK | -3.48% |
| 2023 Q4 | 139.5 Million SEK | 22.88% |
| 2023 FY | 139.5 Million SEK | 93.58% |
| 2023 Q3 | 113.52 Million SEK | 22.65% |
| 2023 Q2 | 92.55 Million SEK | 33.06% |
| 2022 Q2 | 94.63 Million SEK | -6.92% |
| 2022 Q1 | 101.67 Million SEK | -6.77% |
| 2022 Q4 | 72.06 Million SEK | 5.7% |
| 2022 Q3 | 68.17 Million SEK | -27.96% |
| 2022 FY | 72.06 Million SEK | -33.92% |
| 2021 FY | 109.05 Million SEK | -23.75% |
| 2021 Q1 | 127.42 Million SEK | -10.9% |
| 2021 Q3 | 128.03 Million SEK | -0.87% |
| 2021 Q2 | 129.16 Million SEK | 1.37% |
| 2021 Q4 | 109.05 Million SEK | -14.83% |
| 2020 Q2 | 159.38 Million SEK | -2.93% |
| 2020 FY | 143.01 Million SEK | -31.52% |
| 2020 Q4 | 143.01 Million SEK | -8.29% |
| 2020 Q3 | 155.93 Million SEK | -2.16% |
| 2020 Q1 | 164.18 Million SEK | -21.38% |
| 2019 Q3 | 248.33 Million SEK | -9.94% |
| 2019 Q4 | 208.83 Million SEK | -15.9% |
| 2019 FY | 208.83 Million SEK | -44.36% |
| 2019 Q1 | 283.07 Million SEK | -24.58% |
| 2019 Q2 | 275.72 Million SEK | -2.59% |
| 2018 Q4 | 375.3 Million SEK | 7.31% |
| 2018 Q3 | 349.73 Million SEK | -14.08% |
| 2018 FY | 375.3 Million SEK | -25.59% |
| 2018 Q1 | 457.11 Million SEK | -9.37% |
| 2018 Q2 | 407.05 Million SEK | -10.95% |
| 2017 Q3 | 546.84 Million SEK | -4.83% |
| 2017 Q4 | 504.34 Million SEK | -7.77% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 FY | 504.34 Million SEK | -22.07% |
| 2017 Q2 | 574.6 Million SEK | 0.0% |
| 2016 Q4 | 647.21 Million SEK | 0.0% |
| 2016 FY | 647.21 Million SEK | 2735.43% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | 22.82 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AcouSort AB (publ) | 10.37 Million SEK | -1244.219% |
| Active Biotech AB (publ) | 13.4 Million SEK | -941.067% |
| Alzinova AB (publ) | 9.33 Million SEK | -1395.049% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -3051.898% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | -30.872% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 91.09% |
| Camurus AB (publ) | 414.81 Million SEK | 66.37% |
| Cantargia AB (publ) | 54.97 Million SEK | -153.78% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -3534.784% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | -96.157% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -654.315% |
| Kancera AB (publ) | 17.97 Million SEK | -675.965% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -1105.835% |
| LIDDS AB (publ) | 3.75 Million SEK | -3614.137% |
| Lipum AB (publ) | 7.53 Million SEK | -1750.663% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -2604.595% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | -12.521% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -5813.65% |
| NextCell Pharma AB | 13.68 Million SEK | -919.084% |
| Saniona AB (publ) | 86.08 Million SEK | -62.056% |
| Simris Alg AB (publ) | 148.93 Million SEK | 6.335% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -241.425% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -912.978% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 71.068% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | -94.159% |
| Amniotics AB (publ) | 10.54 Million SEK | -1222.679% |
| CombiGene AB (publ) | 4.15 Million SEK | -3256.666% |
| Genovis AB (publ.) | 98.04 Million SEK | -42.282% |
| Mendus AB (publ) | 51.22 Million SEK | -172.334% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -627.943% |
| OncoZenge AB (publ) | 1.69 Million SEK | -8110.889% |
| Xintela AB (publ) | 14.01 Million SEK | -895.384% |
| Ziccum AB (publ) | 6.38 Million SEK | -2083.829% |
| Intervacc AB (publ) | 21.68 Million SEK | -543.464% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -303.153% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -422.327% |
| Corline Biomedical AB | 6.78 Million SEK | -1954.839% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -127.363% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -765.564% |
| Aptahem AB (publ) | 8.99 Million SEK | -1450.408% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -202.085% |
| Fluicell AB (publ) | 8.91 Million SEK | -1464.812% |
| Biovica International AB (publ) | 34.76 Million SEK | -301.251% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -1095.603% |
| Abliva AB (publ) | 16.78 Million SEK | -731.315% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 34.994% |
| 2cureX AB (publ) | 2.93 Million SEK | -4653.083% |
| I-Tech AB | 16.2 Million SEK | -760.864% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 88.237% |
| Cyxone AB (publ) | 4.69 Million SEK | -2871.943% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -946.691% |
| Biosergen AB | 5.08 Million SEK | -2643.422% |
| Nanologica AB (publ) | 79.32 Million SEK | -75.858% |
| SynAct Pharma AB | 51.83 Million SEK | -169.134% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -1654.975% |
| BioInvent International AB (publ) | 90.45 Million SEK | -54.227% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -2585.362% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 23.18% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -7676.087% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -994.656% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -1821.529% |